Literature DB >> 27265220

Outcome of Gleason 3 + 5 = 8 Prostate Cancer Diagnosed on Needle Biopsy: Prognostic Comparison with Gleason 4 + 4 = 8.

Nicholas Harding-Jackson1, Oleksandr N Kryvenko2, Elizabeth E Whittington3, Daniel C Eastwood4, George A Tjionas3, Merce Jorda2, Kenneth A Iczkowski5.   

Abstract

PURPOSE: ISUP (International Society for Urologic Pathology) and WHO adopted prognostic Grade Groups 1 to 5 that simplify prostate cancer grading for prognosis. Grade Group 4 is Gleason score 8 cancer, which is heterogeneous, and it encompasses Gleason score 4 + 4 = 8, 3 + 5 = 8 and 5 + 3 = 8. The comparative prognostic implications of these various Gleason scores had not been studied by urological pathologists after a re-review of slides.
MATERIALS AND METHODS: Patients with a highest biopsy Gleason score of 3 + 5 = 8 or 4 + 4 = 8 were included in the study. Controls were cases with a highest Gleason score of 4 + 3 = 7 or 9-10. A total of 423 prostatic biopsy cases accessioned from 2005 to 2013 at 2 institutions were reviewed. Clinicopathological findings and followup (median 33.4 months) were assessed.
RESULTS: Among Gleason score 8 cancers the cancer status outcome in 51 men with Gleason score 3 + 5 = 8 was marginally worse than in 114 with Gleason score 4 + 4 = 8 (p = 0.04). This was driven by a persistent nonmetastatic (after radiation/hormone therapy) cancer rate of 37% among Gleason score 3 + 5 = 8 cases vs 24% among Gleason score 4 + 4 = 8 cases. Conversely, cancer specific survival at 36-month followup was 97.8% in 3 + 5 cases vs 92.6% in 4 + 4 cases but this was not significant (p = 0.089). Cancer specific survival in the Gleason score 8 group was dichotomized by the presence of cribriform growth (p = 0.018). All Gleason score categories did not differ in the fraction of biopsy cores positive, clinical presentation or pathological findings, including the frequency of Gleason pattern 5, in 70 patients who underwent prostatectomy.
CONCLUSIONS: Using the most current standards of prostate cancer grading the prognosis is not different in Gleason score 3 + 5 = 8 and 4 + 4 = 8 cancers. This justifies including both in Grade Group 4.
Copyright © 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  World Health Organization; biopsy; neoplasm grading; neoplasm recurrence, local; prostatic neoplasms

Mesh:

Year:  2016        PMID: 27265220     DOI: 10.1016/j.juro.2016.05.105

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

1.  Biopsy Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis and Mortality in a Cohort of Men with High Risk Prostate Cancer.

Authors:  Sean P Stroup; Daniel M Moreira; Zinan Chen; Lauren Howard; Jonathan H Berger; Martha K Terris; William J Aronson; Matthew R Cooperberg; Christopher L Amling; Christopher J Kane; Stephen J Freedland
Journal:  J Urol       Date:  2017-07-11       Impact factor: 7.450

2.  Diagnostic performance of 68Ga-PSMA PET/CT for identification of aggressive cribriform morphology in prostate cancer with whole-mount sections.

Authors:  Jie Gao; Chengwei Zhang; Qing Zhang; Yao Fu; Xiaozhi Zhao; Mengxia Chen; Bing Zhang; Danyan Li; Jiong Shi; Feng Wang; Hongqian Guo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-04-25       Impact factor: 9.236

3.  Histopathological Study of the Prostate Cancer Growth Patterns in Relation with the Grading Systems.

Authors:  Tudor Cristian Timotei Popescu; Alex Emilian Stepan; Mirela Marinela Florescu; Cristiana Eugenia Simionescu
Journal:  Curr Health Sci J       Date:  2022-03-31

4.  Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902.

Authors:  Daniel A Hamstra; Stephanie L Pugh; Herbert Lepor; Seth A Rosenthal; Kenneth J Pienta; Leonard Gomella; Christopher Peters; David Paul D'Souza; Kenneth L Zeitzer; Christopher U Jones; William A Hall; Eric Horwitz; Thomas M Pisansky; Luis Souhami; Alan C Hartford; Michael Dominello; Felix Feng; Howard M Sandler
Journal:  Radiother Oncol       Date:  2019-09-17       Impact factor: 6.280

5.  ISUP Group 4 - a Homogenous Group of Prostate Cancers?

Authors:  Thomas Chengxuan Lu; Kim Moretti; Kerri Beckmann; Penelope Cohen; Michael O'Callaghan
Journal:  Pathol Oncol Res       Date:  2017-10-27       Impact factor: 3.201

6.  Differences in survival of prostate cancer Gleason 8-10 disease and the establishment of a new Gleason survival grading system.

Authors:  Yuan Zhou; Changming Lin; Zhihua Hu; Cheng Yang; Rentao Zhang; Yinman Ding; Zhengquan Wang; Sha Tao; Yanmei Qin
Journal:  Cancer Med       Date:  2020-11-01       Impact factor: 4.452

7.  Prostate cancer growth patterns beyond the Gleason score: entering a new era of comprehensive tumour grading.

Authors:  Geert J L H van Leenders; Esther I Verhoef; Eva Hollemans
Journal:  Histopathology       Date:  2020-09-13       Impact factor: 5.087

8.  Alternative prostate cancer grading systems incorporating percent pattern 4/5 (IQ-Gleason) and cribriform architecture (cGrade) improve prediction of outcome after radical prostatectomy.

Authors:  Neslisah Seyrek; Eva Hollemans; Eleni-Rosalina Andrinopoulou; Susanne Osanto; Rob C M Pelger; Henk G van der Poel; Elise Bekers; Sebastiaan Remmers; Ivo G Schoots; Geert J L H van Leenders
Journal:  Virchows Arch       Date:  2022-02-14       Impact factor: 4.535

9.  The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma.

Authors:  Geert J L H van Leenders; Theodorus H van der Kwast; David J Grignon; Andrew J Evans; Glen Kristiansen; Charlotte F Kweldam; Geert Litjens; Jesse K McKenney; Jonathan Melamed; Nicholas Mottet; Gladell P Paner; Hemamali Samaratunga; Ivo G Schoots; Jeffry P Simko; Toyonori Tsuzuki; Murali Varma; Anne Y Warren; Thomas M Wheeler; Sean R Williamson; Kenneth A Iczkowski
Journal:  Am J Surg Pathol       Date:  2020-08       Impact factor: 6.298

10.  Comedonecrosis Gleason pattern 5 is associated with worse clinical outcome in operated prostate cancer patients.

Authors:  Tim Hansum; Eva Hollemans; Esther I Verhoef; Chris H Bangma; John Rietbergen; Susanne Osanto; Rob C M Pelger; Tom van Wezel; Henk van der Poel; Elise Bekers; Jozien Helleman; Sebastiaan Remmers; Geert J L H van Leenders
Journal:  Mod Pathol       Date:  2021-06-26       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.